DNA Medicine Focus Position INOVIO as a partner for scale-up and commercialization of DNA-based therapies, leveraging their clinical-stage pipeline targeting HPV-related diseases, cancer, and infectious diseases to identify co-development or out-licensing opportunities with pharma and biotech firms seeking DNA medicine capabilities.

Commercialization Readiness capitalize on INOVIO's ongoing launch preparations for INO-3107 with Syneos Health by offering support services, marketing analytics, medical affairs, and field readiness solutions to accelerate pre-launch activities or similar programs in a broader HPV/cancer indications portfolio.

Regulatory & Partnerships target collaboration opportunities around regulatory strategy, label negotiations, and payer discussions given upcoming PDUFA date for INO-3107, offering advisory, market access, and health economics expertise to help accelerate approvals and reimbursement pathways.

Manufacturing & Ops address manufacturing deficiencies and supply chain resilience for CELLECTRA devices by proposing quality improvement, supplier diversification, and manufacturing optimization services to minimize risk and ensure scale-up readiness for future DNA vaccine delivery platforms.

Funding & Growth monitor and engage around strategic funding options such as follow-on capital raises or partnerships that align with a $580M funding backdrop, proposing co-development, equity financing, or milestone-driven collaborations to extend clinical programs and broaden the pipeline.